In situ single-cell analysis identifies heterogeneity for PIK3CA mutation and HER2 amplification in HER2-positive breast cancer
Nature Genetics2015Vol. 47(10), pp. 1212–1219
Citations Over TimeTop 10% of 2015 papers
Michalina Janiszewska, Lin Liu, Vanessa Almendro, Yanan Kuang, Cloud P. Paweletz, Rita A. Sakr, Britta Weigelt, Ariella B. Hanker, Sarat Chandarlapaty, Tari A. King, Jorge S. Reis‐Filho, Carlos L. Arteaga, So Yeon Park, Franziska Michor, Kornélia Polyák
Related Papers
- → Mechanisms of Trastuzumab Resistance and Their Clinical Implications(2005)74 cited
- → Intravenous and subcutaneous formulations of trastuzumab, and trastuzumab biosimilars: implications for clinical practice(2021)37 cited
- → Is there any cumulative dose for trastuzumab?(2014)3 cited
- → Cytotoxic Effects of Seleno-Trastuzumab, Trastuzumab (Herceptin) and T-DM-1 (Kadcyla) on Trastuzumab Resistant JIMT-1 Breast Cancer Cells(2014)
- Cardiac toxicity of trastuzumab in elderly patients with breast cancer(2016)